CGON
HealthcareCG Oncology, Inc. Common stock · Biotechnology · $6B
What is CG Oncology, Inc. Common stock?
CG Oncology is a clinical-stage biopharmaceutical company targeting bladder cancer with a novel therapeutic approach. Its pipeline centers on patients who have not responded to the current standard of care, representing a significant unmet medical need.
CG Oncology is developing cretostimogene, an oncolytic viral therapy designed as a potential bladder-sparing treatment for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company targets patients who are unresponsive to BCG therapy — the existing standard of care — and aims to offer an alternative that preserves the bladder. As a clinical-stage company, it does not yet generate product revenue and funds operations through capital markets.
CG Oncology went public in 2024 and is headquartered in Irvine, California.
- Cretostimogene — lead oncolytic viral therapy candidate for NMIBC
- BCG-unresponsive high-risk bladder cancer treatment program
- Bladder-sparing therapeutic approach in clinical development
Is CGON a Good Stock to Buy?
UQS Score rates CGON as Below Average overall, reflecting the realities of its early clinical stage.
The Growth pillar stands out as the clearest positive signal — the company is advancing a differentiated pipeline in a disease area with limited treatment options. The Risk pillar also rates Good, suggesting the balance sheet and operational structure carry manageable near-term risk relative to clinical-stage peers.
Both the Quality and Moat pillars rate Weak, consistent with a pre-revenue company lacking established earnings power or durable competitive advantages. Valuation is rated Elevated, meaning the market is pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CGON pay dividends?
No — CG Oncology, Inc. Common stock does not currently pay a dividend.
CGON does not pay a dividend. As a clinical-stage biopharmaceutical company, capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. This is standard practice for pre-revenue biotechs, where reinvestment into development programs is the primary use of available funds.
When does CGON report earnings?
CG Oncology reports financial results on a quarterly cadence, typical for US-listed equities.
As a clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than product revenue. Pipeline milestones and trial data readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and upcoming reporting dates, visit CG Oncology's investor relations page directly.
CGON Price History
+92.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in CG Oncology, Inc. Common stock?
Based on CG Oncology, Inc. Common stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CGON Long-term Outlook
The Growth pillar rating reflects genuine pipeline momentum — cretostimogene addresses a patient population with few alternatives, and clinical progress could unlock meaningful value. However, the Elevated Valuation pillar signals that much of this potential is already reflected in the share price, leaving limited margin for trial setbacks. The Good Risk rating provides some reassurance about near-term financial stability, but clinical binary events remain the dominant driver of the fundamental outlook.
Growth drivers
- Advancing cretostimogene through clinical trials toward potential regulatory submission
- Large addressable patient population with BCG-unresponsive NMIBC and no approved bladder-sparing alternatives
- Potential to expand the oncolytic viral therapy platform beyond the initial indication
Key risks
- Clinical trial failure or disappointing efficacy data could materially impair the investment case
- Elevated valuation leaves little room for execution missteps or delays
- Ongoing cash consumption typical of clinical-stage biotechs may require future dilutive financing
CGON vs Peers
CGON operates in a competitive clinical-stage biopharma landscape alongside other mid-cap companies pursuing rare and underserved disease indications.
Rhythm focuses on rare genetic obesity disorders rather than oncology, representing a distinct therapeutic area with its own regulatory and commercial dynamics.
Cogent targets precision oncology through kinase inhibition, pursuing a different mechanistic approach to cancer treatment compared to CG Oncology's oncolytic viral strategy.
PTC Therapeutics has a broader rare disease portfolio including approved products, giving it a more established revenue base than the pre-revenue CGON.
Frequently Asked Questions
What does CG Oncology do?
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene, an oncolytic viral therapy for high-risk Non-Muscle Invasive Bladder Cancer. It specifically targets patients who have not responded to BCG therapy — the current standard of care — with the goal of offering a bladder-sparing alternative.
Does CGON pay dividends?
No, CGON does not pay a dividend. The company is pre-revenue and reinvests all available capital into clinical development and operations. Dividend payments are not typical for clinical-stage biotechs at this stage of development.
When does CGON report earnings?
CG Oncology reports on a quarterly cadence, consistent with US-listed public companies. Because it is pre-revenue, reports center on operating expenses and cash position rather than product sales. Check CG Oncology's investor relations page for the latest schedule.
Is CGON a good stock to buy?
UQS Score rates CGON as Below Average overall. The Growth pillar is Strong and Risk rates Good, but Quality and Moat are both Weak, and Valuation is Elevated. This profile reflects a high-potential but high-uncertainty clinical-stage company. View the full pillar breakdown on UQS Score for a complete picture.
Is CGON overvalued?
The UQS Valuation pillar for CGON is rated Elevated, suggesting the current market price embeds significant expectations for clinical and commercial success. For a pre-revenue biotech, valuation is inherently forward-looking and sensitive to trial outcomes.
How does CGON compare to its competitors?
Compared to peers like RYTM, COGT, and PTCT, CGON is distinguished by its focus on oncolytic viral therapy for bladder cancer — a relatively narrow but underserved indication. Some peers have approved products or broader pipelines, which can reduce binary event risk.
What is CGON's market cap bracket?
CGON is classified as a mid-cap stock. This places it in a range where institutional interest is meaningful but liquidity and analyst coverage may be less extensive than large-cap peers in the healthcare sector.
Who founded CG Oncology?
CG Oncology's founding history and leadership background are publicly available through the company's official website and SEC filings. The company completed its IPO in 2024 and is headquartered in Irvine, California.
Is CGON a long-term quality investment?
As a long-term quality indicator, the UQS Score rates CGON Below Average. The Strong Growth pillar reflects pipeline potential, but Weak Quality and Moat scores highlight the absence of established earnings power or durable competitive advantages — key factors for long-term quality assessments.
What is the main competitive advantage of CG Oncology?
CG Oncology's potential edge lies in its oncolytic viral approach to a patient population — BCG-unresponsive NMIBC — that currently has very limited treatment options. However, the UQS Moat pillar rates Weak, reflecting that this advantage is not yet commercially proven.
What sector does CGON belong to?
CGON operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on oncology, targeting bladder cancer patients who have exhausted the current standard-of-care option.
Is CGON a growth stock or value stock?
Based on its UQS profile, CGON leans firmly toward growth — the Growth pillar is rated Strong. However, the Elevated Valuation pillar means investors are already paying a premium for that growth potential, which is a common dynamic in clinical-stage biotech.
Unlock Full CGON Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access full financial metrics and trend data
- ✓Compare CGON against sector peers side by side
- ✓See the complete Quality and Moat breakdown
- ✓Get the full Valuation and Risk deep-dive
- ✓Pro members access the complete analyst view
Pro Analysis
CGON — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 37.1 | 0.0 | 39.0 | 81.3 | 73.9 | 0.0 | — |
CGON — Pillar Breakdown
Quality
— 0.0/100 (25%)CG Oncology, Inc. Common stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 81.3/100 (20%)CG Oncology, Inc. Common stock is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.0/100 (15%)CG Oncology, Inc. Common stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)CG Oncology, Inc. Common stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 39/100 (25%)CG Oncology, Inc. Common stock possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CGON.
Score Composition
Financial Data
More Stock Analysis
How is the CGON UQS Score Calculated?
The UQS (Unified Quality Score) for CG Oncology, Inc. Common stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses CG Oncology, Inc. Common stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether CG Oncology, Inc. Common stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.